NGR-hTNF is a vascular targeting agent belonging to peptide/cytokine complexes, which can selectively target the tumour vasculature.
The randomised, double-blind, placebo-controlled, multicentre Phase III NGR015 trial, will enroll 390 adult patients affected by malignant pleural mesothelioma with disease progressing after standard pemetrexed-based chemotherapy.
The primary endpoint is overall survival, while the secondary endpoints include progression-free survival, disease control rate, safety and patients’ quality of life.
The company expects to announce the results in 2013.
Â